Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers

Journal of Nuclear Cardiology

Volumn 12, Issue 2, 2005, Pages 166-171

  Barrett, Richard J ^a   Lamson, Michael J ^a   Johnson, James ^a   Smith, William B ^b  

^a King Pharmaceuticals Research and Development Inc   (United States)

^b New Orleans Center for Clinical Research   (United States)

Author keywords

A 2A receptor agonist; Binodenoson; Pharmacokinetics; Safety

Indexed keywords

ADENOSINE A2A RECEPTOR AGONIST; BINODENOSON; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DIZZINESS; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA AND VOMITING; NORMAL HUMAN; OPEN STUDY; PARESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; THORAX PAIN; VASODILATATION; VOLUNTEER;

EID: 16244421094     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2004.12.294     Document Type: Editorial

References (16)

1. K.A. Brown Prognostic value of myocardial perfusion imaging state of the art and new developments J Nucl Cardiol 3 1996 516-537
2. G.A. Beller B.L. Zaret Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease Circulation 101 2000 1465-1478
3. R. Hachamavitch D.S. Berman H. Kiat I. Cohen J.A. Cabico J. Friedman et al., Exercise myocardial perfusion SPECT in patients without known coronary artery disease incremental prognostic value and use in risk stratification Circulation 93 1996 905-914
4. H.G. Stratmann B.R. Tamesis L.T. Younis M.D. Wittry M. Amato D.D. Miller Prognostic value of predischarge dipyridamole technetium 99m sestamibi myocardial tomography in medically treated patients with unstable angina Am Heart J 130 1995 734-740
5. R. Hachamovitch D.S. Berman H. Kiat I. Cohen H. Lewin A. Amanullah et al., Incremental prognostic value of adenosine stress myocardial perfusion single-photon emission computed tomography and impact on subsequent management in patients with or suspected of having myocardial ischemia Am J Cardiol 80 1997 426-433
6. A.M. Amanullah D.S. Berman R. Hachamovitch H. Kiat X. Kang J.D. Friedman Identification of severe or extensive coronary artery disease in women by adenosine technetium-99m sestamibi SPECT Am J Cardiol 80 1997 132-137
7. G.V. Heller S.D. Herman M.I. Travin J.I. Baron C. Santos-Ocampo J.R. McClellan Independent prognostic value of intravenous dipyridamole with technetium-99m sestamibi tomographic imaging in predicting cardiac events and cardiac-related hospital admissions J Am Coll Cardiol 26 1995 1202-1208
8. M.D. Cerqueira M.S. Verani M. Schwaiger J. Heo A.S. Iskandrian Investors of the Multicenter Andenoscan Trial Safety profile of adenosine stress perfusion imaging results from the Adenoscan Multicenter Trial Registry J Am Coll Cardiol 23 1994 384-389
9. A. Ranhosky J. Kempthorne-Rawson Intravenous Dipyridamole Thallium Imaging Study Group The safety of intravenous dipyridamole thallium myocardial perfusion imaging Circulation 81 1990 1205-1209
10. 2A receptor stimulation first report in patients of a well tolerated novel agent for stress imaging J Am Coll Cardiol 37A 2001 299A
11. 2A receptor agonist that produces selective coronary vasodilation Drug Dev Res 40 1997 313-324
12. 2A receptor agonist Circulation 94 1996 1726-1732
13. Clinical safety data management definitions and standards for expedited reporting 1995 International Conference on Harmonization (ICH) Guideline for Industry, Federal Register. March 1, (60 FR 11284).
14. 2A adenosine receptor agonist 2-cyclohexylmethylhydrazinoadenosine in the rat Drug Dev Res 42 1997 76-85
15. V. Ralevic G. Burnstock Receptors for purines and pyrimidines Pharmacol Rev 50 1998 413-492
16. 2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging Circulation 109 2004 457-464